Literature DB >> 26653301

Advances in the Treatment of Metastatic Prostate Cancer.

Jong Chul Park1, Mario A Eisenberger2.   

Abstract

During the past several years, there has been substantial progress in the development of treatments for advanced prostate cancer with the approval of multiple new life-prolonging agents using different mechanisms of action. Such progress was attainable because of advances in our understanding of the biology behind mechanisms of androgen receptor pathway activation, complex tumor-microenvironment interaction of bone metastasis, antitumor immunology, and new oncogenic pathways. Continuous efforts are being made to develop new therapeutics with novel mechanisms of action, define the optimal sequences and/or combinations of current agents, and identify reliable surrogate end points to facilitate new drug development.
Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26653301     DOI: 10.1016/j.mayocp.2015.10.010

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  9 in total

1.  Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Authors:  Emanuela Dylgjeri; Christopher McNair; Jonathan F Goodwin; Heather K Raymon; Peter A McCue; Ayesha A Shafi; Benjamin E Leiby; Renée de Leeuw; Vishal Kothari; Jennifer J McCann; Amy C Mandigo; Saswati N Chand; Matthew J Schiewer; Lucas J Brand; Irina Vasilevskaya; Nicolas Gordon; Talya S Laufer; Leonard G Gomella; Costas D Lallas; Edouard J Trabulsi; Felix Y Feng; Ellen H Filvaroff; Kristin Hege; Dana Rathkopf; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2019-07-02       Impact factor: 12.531

2.  SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.

Authors:  ShuYan Liu; Xiao Li; ZhaoMin Lin; Le Su; Shan Yan; BaoXiang Zhao; JunYing Miao
Journal:  Cancer Lett       Date:  2017-12-13       Impact factor: 8.679

3.  Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status.

Authors:  Junlong Wu; Guowen Lin; Yao Zhu; Hailiang Zhang; Guohai Shi; Yijun Shen; Yiping Zhu; Bo Dai; Dingwei Ye
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

4.  Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone.

Authors:  Anais Fradet; Mathilde Bouchet; Carine Delliaux; Manon Gervais; Casina Kan; Claire Benetollo; Francesco Pantano; Geoffrey Vargas; Lamia Bouazza; Martine Croset; Yohann Bala; Xavier Leroy; Thomas J Rosol; Jennifer Rieusset; Akeila Bellahcène; Vincent Castronovo; Jane E Aubin; Philippe Clézardin; Martine Duterque-Coquillaud; Edith Bonnelye
Journal:  Oncotarget       Date:  2016-11-22

5.  Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer.

Authors:  Xinning Wang; Aditi Shirke; Ethan Walker; Rongcan Sun; Gopolakrishnan Ramamurthy; Jing Wang; Lingpeng Shan; Joey Mangadlao; Zhipeng Dong; Jing Li; Ziying Wang; Mark Schluchter; Dong Luo; Yu Wang; Shaun Stauffer; Susann Brady-Kalnay; Christopher Hoimes; Zhenghong Lee; James P Basilion
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639

6.  A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.

Authors:  Xinning Wang; Rongcan Sun; Jing Wang; Jing Li; Ethan Walker; Aditi Shirke; Gopolakrishnan Ramamurthy; Lingpeng Shan; Dong Luo; Lauren Carmon; James P Basilion
Journal:  Theranostics       Date:  2022-02-21       Impact factor: 11.556

7.  Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases.

Authors:  Bo Peng; Cheng Yang; Jian He
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

8.  RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells.

Authors:  Binbin Yin; Zhenping Liu; Yiyun Wang; Xuchu Wang; Weiwei Liu; Pan Yu; Xiuzhi Duan; Chunhua Liu; Yuhua Chen; Yurong Zhang; Xiaoyan Pan; Hangping Yao; Zhaoping Liao; Zhihua Tao
Journal:  Oncol Rep       Date:  2017-04-19       Impact factor: 4.136

9.  Prostate-specific membrane antigen targeted gold nanoparticles for prostate cancer radiotherapy: does size matter for targeted particles?

Authors:  Dong Luo; Xinning Wang; Sophia Zeng; Gopalakrishnan Ramamurthy; Clemens Burda; James P Basilion
Journal:  Chem Sci       Date:  2019-07-18       Impact factor: 9.825

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.